But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

A turbulent series of events surrounding the supply of Eli Lilly ... obesity, after almost two years. By law, that should have prohibited compound pharmacies from making copies of the drug ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to ... platform to support its preclinical drug discovery efforts in obesity and related metabolic conditions ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

Eli Lilly's product pipeline is anchored by its GLP-1 receptor agonists, Mounjaro (tirzepatide) and Zepbound. These drugs have shown impressive results in treating type 2 diabetes and obesity, ...

Eli Lilly’s third-quarter ... GLP-1 drugs were affected by drug wholesalers buying less product. The diabetes treatment Mounjaro brought in $3.1 billion and the obesity medication Zepbound ...

Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Q3 earnings call that wholesalers decreased their ...

One area of heightened focus is the fast-growing market for obesity and diabetes drugs like Mounjaro and Ozempic. Eli Lilly and Novo Nordisk are seeking to broaden insurance coverage for such ...